A Study to Evaluate Nasal Vestibulitis Symptoms in Patients Undergoing Systemic Antineoplastic Therapy
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 18-000065
- Mankato, Minnesota: 18-000065
- Albert Lea, Minnesota: 18-000065
- Austin, Minnesota: 18-000065
Sponsor Protocol Number: MC1893
About this study
The purpose of this study is to evaluate treatment-emergent nasal vestibulitis symptoms in patients undergoing systemic antineoplastic therapy.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
- ≥ 18 years of age and be diagnosed with cancer.
- Provide informed consent.
- Ability to complete questionnaire(s) by themselves or with assistance.
- Planned use of one of the defined systemic, antineoplastic therapies.
- Willingness to complete questionnaires with each dose of therapy.
- Plan to receive chemotherapy for the following 3-4 months OR a minimum of 4 cycles of chemotherapy given at intervals of 2 weeks or longer.
- No prior chemotherapy over the previous 3 months.
Exclusion Criteria:
- Predisposition to frequent nosebleeds (more than once per month).
- Verbal baseline nasal dryness, pain, bleeding, or scabbing ≥ 2 on a 10 point scale (from mild=1 to severe=10).
- Planned receipt of two of the studied agents concurrently (e.g., abraxane and bevacizumab).
- Planned participation in a placebo-controlled trial.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
Contact |
Rochester, Minn.
Mayo Clinic principal investigator Charles Loprinzi, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Mankato, Minn.
Mayo Clinic principal investigator Stephan Thome, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Albert Lea, Minn.
Mayo Clinic principal investigator Mina Hanna, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
Austin, Minn.
Mayo Clinic principal investigator Mina Hanna, M.D. |
Closed for enrollment |
Contact information:
Cancer Center Clinical Trials Referral Office
(855) 776-0015
|
More information
Publications
Publications are currently not available